/RGT.L
RGT.L Stock - Argent BioPharma Limited
Healthcare|Drug Manufacturers - Specialty & GenericLSE
$6.00-7.69%
$0.50 (-7.69%) • Dec 30
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $6.60
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RGT.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.94 – $6.06
TARGET (TP)$6.90
STOP LOSS$5.52
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.08
52W High$29.60
52W Low$0.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $891,083 | $3.39M | $4.73M | $2.96M | $1.16M |
| Gross Profit | $203,697 | $1.45M | $1.81M | $1.31M | $97,283 |
| Gross Margin | 22.9% | 42.8% | 38.3% | 44.2% | 8.4% |
| Operating Income | $-16,700,000 | $-15,598,000 | $-14,261,000 | $-12,070,000 | $-10,389,000 |
| Net Income | $-17,531,000 | $-20,824,000 | $-20,347,000 | $-15,870,000 | $-10,785,000 |
| Net Margin | -1967.4% | -614.6% | -430.0% | -535.6% | -931.3% |
| EPS | $-0.47 | $-7.11 | $-7.63 | $-7.01 | $-7.34 |
Company Overview
No company description available.
Loading analyst ratings...
Earnings History & Surprises
RGT.LBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.06
Q3 2024
EPS Surprise History
Q4 20
No data
Q2 21
No data
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q2 24
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 28, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q3 2024 | Aug 30, 2024 | — | $-0.06 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.09 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.83 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1.32 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-1.46 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.95 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.30 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.21 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.55 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-2.61 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.74 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-1.47 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.34 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-2.14 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-1.80 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-1.10 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-1.21 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-1.68 | — | — |
Latest News
Loading news...
Frequently Asked Questions about RGT.L
What is RGT.L's current stock price?
Argent BioPharma Limited (RGT.L) is currently trading at $6.00 per share. The stock has moved -7.69% today.
What is the analyst price target for RGT.L?
No analyst price targets are currently available for this stock.
What sector is Argent BioPharma Limited in?
Argent BioPharma Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the LSE exchange.
What is RGT.L's market cap?
Argent BioPharma Limited has a market capitalization of $0.00 billion, making it a small-cap company.
Does RGT.L pay dividends?
No, Argent BioPharma Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBELL.L
Belluscura plc
$0.75
Mkt Cap: $0.3B
CLAI.L
Cel AI PLC
$0.13
Mkt Cap: $0.1B
CNSL.L
Cambridge Nutritional Sciences plc
$1.95
Mkt Cap: $0.5B
DEST.L
Destiny Pharma plc
$3.00
Mkt Cap: $0.3B
HELD.L
Hellenic Dynamics Plc
$0.95
Mkt Cap: $0.1B
KNB.L
Kanabo Group Plc
$0.23
Mkt Cap: $0.1B
LLAI.L
LungLife AI, Inc.
$4.15
Mkt Cap: $0.1B
ONC.L
Oncimmune Holdings plc
$1.14
Mkt Cap: $0.1B
RENE.L
ReNeuron Group plc
$3.38
Mkt Cap: $0.2B
TCF.L
Theracryf Plc
$0.20
Mkt Cap: $0.4B
Explore stocks similar to RGT.L for comparison